Poolbeg Pharma Secures First Oncology Patent for POLB 001
Episode 2353, Mar 31, 07:12 AM
Share
Subscribe
Poolbeg Pharma announces its first granted patent for POLB 001 in cancer immunotherapy-induced CRS, strengthening its global IP position. The milestone supports future partnering opportunities as the company advances toward key clinical data in 2026.